135 related articles for article (PubMed ID: 15615531)
1. 4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}piperazine as a potent and selective melanocortin-4 receptor antagonist--design, synthesis, and characterization.
Chen C; Pontillo J; Fleck BA; Gao Y; Wen J; Tran JA; Tucci FC; Marinkovic D; Foster AC; Saunders J
J Med Chem; 2004 Dec; 47(27):6821-30. PubMed ID: 15615531
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological and pharmacokinetic characterization of 2-piperazine-alpha-isopropyl benzylamine derivatives as melanocortin-4 receptor antagonists.
Chen C; Tucci FC; Jiang W; Tran JA; Fleck BA; Hoare SR; Wen J; Chen T; Johns M; Markison S; Foster AC; Marinkovic D; Chen CW; Arellano M; Harman J; Saunders J; Bozigian H; Marks D
Bioorg Med Chem; 2008 May; 16(10):5606-18. PubMed ID: 18417348
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor.
Tran JA; Jiang W; Tucci FC; Fleck BA; Wen J; Sai Y; Madan A; Chen TK; Markison S; Foster AC; Hoare SR; Marks D; Harman J; Chen CW; Arellano M; Marinkovic D; Bozigian H; Saunders J; Chen C
J Med Chem; 2007 Dec; 50(25):6356-66. PubMed ID: 17994683
[TBL] [Abstract][Full Text] [Related]
4. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
Wilczynski A; Wang XS; Joseph CG; Xiang Z; Bauzo RM; Scott JW; Sorensen NB; Shaw AM; Millard WJ; Richards NG; Haskell-Luevano C
J Med Chem; 2004 Apr; 47(9):2194-207. PubMed ID: 15084118
[TBL] [Abstract][Full Text] [Related]
5. Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines.
Tucci FC; White NS; Markison S; Joppa M; Tran JA; Fleck BA; Madan A; Dyck BP; Parker J; Pontillo J; Arellano LM; Marinkovic D; Jiang W; Chen CW; Gogas KR; Goodfellow VS; Saunders J; Foster AC; Chen C
Bioorg Med Chem Lett; 2005 Oct; 15(19):4389-95. PubMed ID: 16098742
[TBL] [Abstract][Full Text] [Related]
6. Piperazinebenzylamines as potent and selective antagonists of the human melanocortin-4 receptor.
Pontillo J; Tran JA; Fleck BA; Marinkovic D; Arellano M; Tucci FC; Lanier M; Nelson J; Parker J; Saunders J; Murphy B; Foster AC; Chen C
Bioorg Med Chem Lett; 2004 Nov; 14(22):5605-9. PubMed ID: 15482933
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia.
Chen C; Jiang W; Tucci F; Tran JA; Fleck BA; Hoare SR; Joppa M; Markison S; Wen J; Sai Y; Johns M; Madan A; Chen T; Chen CW; Marinkovic D; Arellano M; Saunders J; Foster AC
J Med Chem; 2007 Nov; 50(22):5249-52. PubMed ID: 17918824
[TBL] [Abstract][Full Text] [Related]
8. Identification of agonists and antagonists of the human melanocortin-4 receptor from piperazinebenzylamines.
Tran JA; Pontillo J; Arellano M; White NS; Fleck BA; Marinkovic D; Tucci FC; Lanier M; Nelson J; Saunders J; Foster AC; Chen C
Bioorg Med Chem Lett; 2005 Feb; 15(3):833-7. PubMed ID: 15664867
[TBL] [Abstract][Full Text] [Related]
9. Substituted NDP-MSH peptides paired with mutant melanocortin-4 receptors demonstrate the role of transmembrane 6 in receptor activation.
Fleck BA; Ling N; Chen C
Biochemistry; 2007 Sep; 46(37):10473-83. PubMed ID: 17713970
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of potent and selective 1,3,4-trisubstituted-2-oxopiperazine based melanocortin-4 receptor agonists.
Tian X; Mishra RK; Switzer AG; Hu XE; Kim N; Mazur AW; Ebetino FH; Wos JA; Crossdoersen D; Pinney BB; Farmer JA; Sheldon RJ
Bioorg Med Chem Lett; 2006 Sep; 16(17):4668-73. PubMed ID: 16766182
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and structure-activity relationships of novel arylpiperazines as potent and selective agonists of the melanocortin subtype-4 receptor.
Richardson TI; Ornstein PL; Briner K; Fisher MJ; Backer RT; Biggers CK; Clay MP; Emmerson PJ; Hertel LW; Hsiung HM; Husain S; Kahl SD; Lee JA; Lindstrom TD; Martinelli MJ; Mayer JP; Mullaney JT; O'Brien TP; Pawlak JM; Revell KD; Shah J; Zgombick JM; Herr RJ; Melekhov A; Sampson PB; King CH
J Med Chem; 2004 Jan; 47(3):744-55. PubMed ID: 14736255
[TBL] [Abstract][Full Text] [Related]
12. Anxiolytic-like and antidepressant-like activities of MCL0129 (1-[(S)-2-(4-fluorophenyl)-2-(4-isopropylpiperadin-1-yl)ethyl]-4-[4-(2-methoxynaphthalen-1-yl)butyl]piperazine), a novel and potent nonpeptide antagonist of the melanocortin-4 receptor.
Chaki S; Hirota S; Funakoshi T; Suzuki Y; Suetake S; Okubo T; Ishii T; Nakazato A; Okuyama S
J Pharmacol Exp Ther; 2003 Feb; 304(2):818-26. PubMed ID: 12538838
[TBL] [Abstract][Full Text] [Related]
13. A potent and selective nonpeptide antagonist of the melanocortin-4 receptor induces food intake in satiated mice.
Pontillo J; Tran JA; Markison S; Joppa M; Fleck BA; Marinkovic D; Arellano M; Tucci FC; Lanier M; Nelson J; Saunders J; Hoare SR; Foster AC; Chen C
Bioorg Med Chem Lett; 2005 May; 15(10):2541-6. PubMed ID: 15863313
[TBL] [Abstract][Full Text] [Related]
14. Mapping the binding site of melanocortin 4 receptor agonists: a hydrophobic pocket formed by I3.28(125), I3.32(129), and I7.42(291) is critical for receptor activation.
Hogan K; Peluso S; Gould S; Parsons I; Ryan D; Wu L; Visiers I
J Med Chem; 2006 Feb; 49(3):911-22. PubMed ID: 16451057
[TBL] [Abstract][Full Text] [Related]
15. Melanocortin 4 receptors interact with antimicrobial frog peptide analogues.
Do EU; Jo EB; Choi G; Piao LZ; Shin J; Seo MD; Kang SJ; Lee BJ; Kim KH; Kim JB; Kim SI
Biochem Biophys Res Commun; 2006 May; 343(4):1094-100. PubMed ID: 16579969
[TBL] [Abstract][Full Text] [Related]
16. Identification of differential melanocortin 4 receptor agonist profiles at natively expressed receptors in rat cortical astrocytes and recombinantly expressed receptors in human embryonic kidney cells.
Selkirk JV; Nottebaum LM; Lee J; Yang W; Foster AC; Lechner SM
Neuropharmacology; 2007 Feb; 52(2):459-66. PubMed ID: 17095023
[TBL] [Abstract][Full Text] [Related]
17. Melanocortin receptor 4 is induced in nerve-injured motor and sensory neurons of mouse.
Tanabe K; Gamo K; Aoki S; Wada K; Kiyama H
J Neurochem; 2007 May; 101(4):1145-52. PubMed ID: 17286587
[TBL] [Abstract][Full Text] [Related]
18. Dynamic regulation of hypothalamic neuropeptide gene expression and food intake by melanocortin analogues and reversal with melanocortin-4 receptor antagonist.
Kim RY; Shin SW; Kim BJ; Lee W; Baik JH
Biochem Biophys Res Commun; 2005 Apr; 329(4):1178-85. PubMed ID: 15766551
[TBL] [Abstract][Full Text] [Related]
19. Novel piperazines: potent melanocortin-4 receptor antagonists with anxiolytic-like activity.
Nozawa D; Okubo T; Ishii T; Takamori K; Chaki S; Okuyama S; Nakazato A
Bioorg Med Chem; 2007 Mar; 15(6):2375-85. PubMed ID: 17267226
[TBL] [Abstract][Full Text] [Related]
20. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice.
Nicholson JR; Kohler G; Schaerer F; Senn C; Weyermann P; Hofbauer KG
J Pharmacol Exp Ther; 2006 May; 317(2):771-7. PubMed ID: 16436498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
